CSL Finance Ltd
CSLFINANCECSL Finance Ltd compounds quietly. Returns above 15% and growth without drama — priced like it.
The sharpest disagreement: annual EPS moved +19.5% against a −33.7% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (48 weeks in) while the P/BV sits at the 20th percentile of its own 10-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, and gross NPA has moved to 1.10%. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
CSL Finance Ltd trades at ₹212, in a downtrend and 48 weeks into that stage. That is −17.0% against its own 200-day average. It sits at 0% of a 52-week range of ₹212 to ₹318. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is in a downtrend — week 48 of stage 4, confirmed. At ₹212 it trades −17.0% versus its 200-day average and sits at 0% of its 52-week range (₹212–₹318).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +817% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-01) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each ₹1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
CSL Finance Ltd trades at 0.8× P/BV, near the bottom of its own range — cheaper only 20% of the time. Its long-run median P/BV is 1.2×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/BV of 0.8× is near the bottom of its own range — cheaper only 20% of the time, against a long-run median of 1.2× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year book value grew while the price moved −33.7% — price and book moved together, holding the multiple in its range.
The price move, decomposed: over 5y, of the +10.6%/yr price move, ~+15.7%/yr came from book-value growth and ~−5.1 pp from the multiple (compressing); over 10y, of the +19.6%/yr price move, ~+16.2%/yr came from book-value growth and ~+3.4 pp from the multiple (expanding). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the book-value line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
At its price on 13 June 2026, CSL Finance Ltd was priced for profit growth of about −2.1% a year. Profit itself has compounded 20.8% a year over the past 10 years. The market pays that at 0.8× P/BV, the 20th percentile of its own 10-year range.
What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is below what this company has actually delivered. Both readings sit on the same earnings, so they are one reading rather than two.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements. Every other number on this page is read off the live quote.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
CSL Finance Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROE holding at 15.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +18.5% | +29.8% | +32.8% | +19.3% |
| Profit | +19.4% | +23.2% | +25.2% | +20.8% |
| EPS | +19.5% | +19.8% | +20.5% | +15.0% |
| Share price | −33.7% | −14.5% | +10.6% | +19.6% |
4-Factor Sector Score
56.6/100 — rank 7 of 33 in Finance & Investments - Others · 87% evidence confidence
CSL Finance Ltd scores 56.6 out of 100 against the 33 companies it is compared with in Finance & Investments - Others, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 20.3 + 22.1 + 12 + 2.2 = 56.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fee and other income.
CSL Finance Ltd reported ₹69.0 Cr of income in the Mar 26 quarter, +21.1% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 19.3% a year. The last full year, FY26, came in at ₹256 Cr. The last four reported quarters add to ₹256 Cr.
FY26 revenue came in at ₹256 Cr (+18.5% on the year), capping 10 years at 19.3% compound. The latest quarter (Mar 26) printed ₹69.0 Cr, +21.1% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +19.0% growth against the decade's 19.3% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +19.1% over the last 4 quarters against +24.6%/yr over the last 8 — rolling over; TTM profit +18.1% vs +15.2%/yr — stabilising.
Net margin Net margin — what the bank keeps of every ₹100 of revenue after every cost, provision and tax. It is the cleanest single margin we can read for a lender.
CSL Finance Ltd's net margin is 27.5% in the Mar 26 quarter, −5.8 percentage points against the same quarter a year ago. Across 13 fiscal years the net margin has ranged 6.1% to 45.2%. The current quarter sits inside that band.
The latest quarter's net margin is 27.5%, −5.8 pp against the same quarter a year ago. Across 13 fiscal years the net margin has ranged 6.1%–45.2%.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
CSL Finance Ltd earned ₹19.0 Cr of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹86.0 Cr. The 10-year compound rate is 20.8%. That is 27.5% of the quarter's revenue. The same quarter a year earlier earned ₹19.0 Cr.
Mar 26 profit was ₹19.0 Cr, +0.0% year on year. On the full year, FY26 printed ₹86.0 Cr (+19.4%), and the 10-year compound rate is 20.8%.
🚨 Why profit moved: revenue contributed +21.1% and the margin −5.8 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +18.4% vs revenue +19.0%. Profit and revenue are moving roughly in step.
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
CSL Finance Ltd's gross NPA is 1.10% of the loan book in Mar 26, up from 0.46% a year ago. Net of provisions already set aside, 0.81% remains. Across the 12 quarters held here the book has ranged 0.38% to 1.10%. Falling NPAs are a loan book healing; rising NPAs are damage arriving.
Mar 26: gross NPA at 1.10% and net NPA at 0.81%, against 0.46% / 0.34% a year ago. Over the 12 quarters we hold, the book's worst reading was 1.10% and its best is 0.38%.
The synthesis: profit growth at a bank is only as good as the book behind it, and this book is not yet on a clear healing streak. A note on depth: quarterly provisioning detail is not in our numbers yet, so this ladder reads levels and trend, not the cost of the cleanup.
🚨 Why the ladder moved: recoveries, write-offs and slippages each play a part, and that split sits below what we hold — the numbers show the healing; the driver mix does not travel with them.
The loan book We read the loan book through revenue — when the book grows, revenue grows with it. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
CSL Finance Ltd's revenue grew +18.5% in FY26 to ₹256 Cr, so the book is growing. The latest quarter ran +21.1% year on year. The net margin on that income is 27.5%, −5.8 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.
FY26 revenue was ₹256 Cr, +18.5% on the year, and the latest quarter ran +21.1% year on year. The net margin on that revenue is 27.5% this quarter (−5.8 pp YoY) — growth with a narrowing margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — gross NPA is the loan-quality read we carry here.
Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.
CSL Finance Ltd earns a return on equity of 15% in FY26. Its trough over the ladder below was 9% in FY15. On the asset side every ₹100 of the balance sheet earned about ₹8.96, which is the return before leverage is applied.
FY26 ROE came in at 15%, recovered from a FY15 trough of 9%. On assets, the latest reading is about 8.96% — every ₹100 the bank deploys earns roughly ₹8.96 a year. That clears the bar a bank must beat for its book value to compound.
Why ROE moved: profit compounded 20.8% a year over 10 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 2.4 points of CSL Finance Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 0.1% of the company. Domestic institutions moved +2.3 points over the same window, to 3.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −2.4 points over 8 quarters to 0.1%; Domestic institutions: +2.3 points over 8 quarters to 3.5%; Promoters: +0.7 points over 8 quarters to 48.2%.
Why the register moved: rotation — foreign institutions −2.4 points against domestic institutions +2.3 points over 8 quarters, with promoters +0.7 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
CSL Finance Ltd: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Abans Financial Services LtdAFSL | 69.1/100Favorable setup80% evidence | BASING | 23.9/35 Income 100% · PAT 17.9% 81% evidence | 14.3/25 ROA 3.6% · ROE 8.3% · GNPA — 68% evidence | 16.8/20 P/BV 0.83× · P/BV÷ROE 0.1 100% evidence | 14.1/20 RS sector 21% · RS bench -1.6% · 1Y -7.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 23.9 + 14.3 + 16.8 + 14.1 = 69.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Fedders Holding LtdFEDDERSHOL | 66.7/100Favorable setup80% evidence | BREAKING OUT | 25.1/35 Income -6.4% · PAT 100% 81% evidence | 18.3/25 ROA 10.9% · ROE 11.6% · GNPA — 68% evidence | 13.6/20 P/BV 1.18× · P/BV÷ROE 0.1 70% evidence | 9.7/20 RS sector -5.8% · RS bench -8.9% · 1Y -4.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 25.1 + 18.3 + 13.6 + 9.7 = 66.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Saraswati Commercial (India) LtdZSARACOM | 65.0/100Favorable setup80% evidence | TURNING | 30.6/35 Income 100% · PAT 100% 81% evidence | 15.1/25 ROA 7.6% · ROE 8.9% · GNPA — 68% evidence | 10.8/20 P/BV 1.21× · P/BV÷ROE 0.14 100% evidence | 8.5/20 RS sector -17% · RS bench 3.2% · 1Y -5.8%4 of 6 weeks ahead 70% evidence |
| Exact sum: 30.6 + 15.1 + 10.8 + 8.5 = 65 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4BF Investment LtdBFINVEST | 64.9/100Mixed-positive evidence86% evidence | BREAKING OUT | 27.2/35 Income 22.2% · PAT 100% 81% evidence | 11.8/25 ROA 3% · ROE 3.6% · GNPA — 68% evidence | 8.0/20 P/BV 0.2× · P/BV÷ROE 0.06 100% evidence | 17.9/20 RS sector 8.5% · RS bench 5.5% · 1Y 2.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 11.8 + 8 + 17.9 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Gretex Corporate Services LtdGCSL | 64.2/100Mixed-positive evidence86% evidence | LEADER | 24.5/35 Income -19.4% · PAT 100% 81% evidence | 18.4/25 ROA 11.5% · ROE 12.7% · GNPA — 68% evidence | 1.6/20 P/BV 7.15× · P/BV÷ROE 0.56 100% evidence | 19.7/20 RS sector 45.1% · RS bench 42.3% · 1Y 76.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 18.4 + 1.6 + 19.7 = 64.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 6Algoquant Fintech LtdALGOQUANT | 59.5/100Mixed-positive evidence74% evidence | BREAKING OUT | 19.9/35 Income 15.7% · PAT 100% 81% evidence | 20.3/25 ROA 12% · ROE 28.4% · GNPA — 68% evidence | 4.5/20 P/BV 13.81× · P/BV÷ROE 0.49 70% evidence | 14.8/20 RS sector 4.5% · RS bench 4.5% · 1Y -11.4%5 of 10 weeks ahead 70% evidence |
| Exact sum: 19.9 + 20.3 + 4.5 + 14.8 = 59.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 7CSL Finance Ltdthis pageCSLFINANCE | 56.6/100Mixed-positive evidence87% evidence | 20.3/35 Income 19.1% · PAT 18.1% 67% evidence | 22.1/25 ROA 9% · ROE 14.8% · GNPA 1.1% 95% evidence | 12.0/20 P/BV 0.78× · P/BV÷ROE 0.05 100% evidence | 2.2/20 RS sector -19.4% · RS bench -21.1% · 1Y -27.9%0 of 8 weeks ahead to 2026-07-19 100% evidence | |
| Exact sum: 20.3 + 22.1 + 12 + 2.2 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Bengal & Assam Company LtdBENGALASM | 55.3/100Mixed-positive evidence64% evidence | 18.2/35 Income 11.7% · PAT 11.8% 62% evidence | 12.8/25 ROA — · ROE 8.1% · GNPA — 34% evidence | 16.1/20 P/BV 0.66× · P/BV÷ROE 0.08 100% evidence | 8.2/20 RS sector -9.4% · RS bench 1.2% · 1Y -11.7%2 of 2 weeks ahead to 2026-06-07 70% evidence | |
| Exact sum: 18.2 + 12.8 + 16.1 + 8.2 = 55.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Mufin Green Finance LtdMUFIN | 54.7/100Mixed-positive evidence82% evidence | LEADER | 23.9/35 Income 27.8% · PAT 100% 86% evidence | 11.0/25 ROA 1.3% · ROE 6.7% · GNPA — 72% evidence | 3.7/20 P/BV 4.69× · P/BV÷ROE 0.7 70% evidence | 16.1/20 RS sector 21.2% · RS bench 18.6% · 1Y 53.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 11 + 3.7 + 16.1 = 54.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10STEL Holdings LtdSTEL | 52.9/100Mixed-positive evidence80% evidence | BREAKING OUT | 25.7/35 Income 20.7% · PAT 21.6% 81% evidence | 8.8/25 ROA 1.2% · ROE 1.2% · GNPA — 68% evidence | 2.4/20 P/BV 0.67× · P/BV÷ROE 0.57 100% evidence | 16.0/20 RS sector 20.5% · RS bench 17.2% · 1Y 38.9%8 of 10 weeks ahead 70% evidence |
| Exact sum: 25.7 + 8.8 + 2.4 + 16 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Dolat Algotech LtdDOLATALGO | 52.7/100Mixed-positive evidence80% evidence | BASING | 8.3/35 Income -11.6% · PAT -21.2% 81% evidence | 18.1/25 ROA 8.5% · ROE 12.1% · GNPA — 68% evidence | 17.3/20 P/BV 1.08× · P/BV÷ROE 0.09 100% evidence | 9.0/20 RS sector -0.8% · RS bench -12% · 1Y -21.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 8.3 + 18.1 + 17.3 + 9 = 52.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12PTC India Financial Services LtdPFS | 51.6/100Mixed-positive evidence80% evidence | ASLEEP | 12.3/35 Income -22.7% · PAT -27.8% 81% evidence | 16.7/25 ROA 6.5% · ROE 11% · GNPA — 68% evidence | 16.6/20 P/BV 0.59× · P/BV÷ROE 0.05 100% evidence | 6.0/20 RS sector -7.1% · RS bench -14.2% · 1Y -25.5%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.3 + 16.7 + 16.6 + 6 = 51.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Balmer Lawrie Investment LtdBLIL | 50.3/100Mixed-positive evidence86% evidence | ASLEEP | 14.2/35 Income 8.8% · PAT 4.1% 81% evidence | 18.2/25 ROA 7.9% · ROE 12.7% · GNPA — 68% evidence | 13.6/20 P/BV 1.09× · P/BV÷ROE 0.09 100% evidence | 4.3/20 RS sector -4.3% · RS bench -7% · 1Y -16.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 18.2 + 13.6 + 4.3 = 50.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 14Master Trust LtdMASTERTR | 49.4/100Mixed-negative evidence80% evidence | ASLEEP | 12.8/35 Income 7% · PAT 8.1% 81% evidence | 18.8/25 ROA 5.6% · ROE 17.3% · GNPA — 68% evidence | 15.4/20 P/BV 1.18× · P/BV÷ROE 0.07 70% evidence | 2.4/20 RS sector -21.8% · RS bench -24.9% · 1Y -52.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 18.8 + 15.4 + 2.4 = 49.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15Consolidated Finvest & Holdings LtdCONSOFINVT | 46.6/100Mixed-negative evidence86% evidence | BREAKING OUT | 7.9/35 Income -9.1% · PAT -43.9% 81% evidence | 13.5/25 ROA 4.3% · ROE 5% · GNPA — 68% evidence | 6.9/20 P/BV 0.75× · P/BV÷ROE 0.15 100% evidence | 18.3/20 RS sector 28.6% · RS bench 26.1% · 1Y 40.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 13.5 + 6.9 + 18.3 = 46.6 · Decision use: Price leads the evidence: RS versus the benchmark is 26.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16VLS Finance LtdVLSFINANCE | 45.1/100Mixed-negative evidence80% evidence | FADING | 18.1/35 Income -8.4% · PAT 91.7% 81% evidence | 7.4/25 ROA 1% · ROE 0.9% · GNPA — 68% evidence | 4.8/20 P/BV 0.38× · P/BV÷ROE 0.4 100% evidence | 14.8/20 RS sector 9.4% · RS bench 2.5% · 1Y 10.4%3 of 10 weeks ahead 70% evidence |
| Exact sum: 18.1 + 7.4 + 4.8 + 14.8 = 45.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Finkurve Financial Services LtdFINKURVE | 44.7/100Mixed-negative evidence74% evidence | TURNING | 20.9/35 Income 59.6% · PAT 62.2% 81% evidence | 13.8/25 ROA 2.1% · ROE 9.4% · GNPA — 68% evidence | 5.9/20 P/BV 2.96× · P/BV÷ROE 0.31 70% evidence | 4.1/20 RS sector -34.3% · RS bench -15.2% · 1Y -34.3%2 of 11 weeks ahead 70% evidence |
| Exact sum: 20.9 + 13.8 + 5.9 + 4.1 = 44.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18PTL Enterprises LtdPTL | 44.2/100Mixed-negative evidence75% evidence | ASLEEP | 16.4/35 Income 0% · PAT 13.5% 52% evidence | 13.7/25 ROA 3.3% · ROE 5.5% · GNPA — 68% evidence | 8.0/20 P/BV 0.61× · P/BV÷ROE 0.11 100% evidence | 6.1/20 RS sector -1.8% · RS bench -4.3% · 1Y -2.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 13.7 + 8 + 6.1 = 44.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Grand Oak Canyons Distillery LtdGRANDOAK | 43.9/100Mixed-negative evidence65% evidence | BREAKING OUT | 23.4/35 Income 100% · PAT 100% 54% evidence | 4.0/25 ROA 0.1% · ROE 0% · GNPA — 72% evidence | 3.6/20 P/BV 2.33× · P/BV÷ROE 233 70% evidence | 12.9/20 RS sector 2% · RS bench 2.1% · 1Y 92.5%5 of 7 weeks ahead 70% evidence |
| Exact sum: 23.4 + 4 + 3.6 + 12.9 = 43.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Industrial & Prudential Investment Company LtdINDPRUD | 43.7/100Mixed-negative evidence80% evidence | ASLEEP | 12.3/35 Income -40% · PAT -3.2% 81% evidence | 15.4/25 ROA 7.3% · ROE 7.7% · GNPA — 68% evidence | 5.7/20 P/BV 1.24× · P/BV÷ROE 0.16 100% evidence | 10.3/20 RS sector -3.5% · RS bench 2.5% · 1Y -8.7%2 of 7 weeks ahead 70% evidence |
| Exact sum: 12.3 + 15.4 + 5.7 + 10.3 = 43.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Authum Investment & Infrastructure LtdAIIL | 43.7/100Mixed-negative evidence70% evidence | BREAKING OUT | 8.4/35 Income -34.6% · PAT -48.8% 62% evidence | 15.2/25 ROA — · ROE 13.1% · GNPA — 34% evidence | 5.2/20 P/BV 3.27× · P/BV÷ROE 0.25 100% evidence | 14.9/20 RS sector 5.6% · RS bench 2.5% · 1Y -0.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 8.4 + 15.2 + 5.2 + 14.9 = 43.7 · Decision use: Price leads the evidence: RS versus the benchmark is 2.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22NBI Industrial Finance Company LtdNBIFIN | 42.3/100Mixed-negative evidence69% evidence | TURNING | 20.8/35 Income 55.5% · PAT 65.2% 33% evidence | 6.0/25 ROA 0.3% · ROE 0.4% · GNPA — 68% evidence | 4.5/20 P/BV 0.23× · P/BV÷ROE 0.55 100% evidence | 11.0/20 RS sector -1.8% · RS bench -4.9% · 1Y -19.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 6 + 4.5 + 11 = 42.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23PNB Gilts LtdPNBGILTS | 40.1/100Mixed-negative evidence80% evidence | FADING | 9.0/35 Income -5.3% · PAT -69.7% 81% evidence | 9.8/25 ROA 0.7% · ROE 11.1% · GNPA — 68% evidence | 15.2/20 P/BV 0.84× · P/BV÷ROE 0.08 100% evidence | 6.1/20 RS sector -13.5% · RS bench -7% · 1Y -21.4%8 of 10 weeks ahead 70% evidence |
| Exact sum: 9 + 9.8 + 15.2 + 6.1 = 40.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24Capital India Finance LtdCIFL | 40.0/100Thin evidence · provisional57% evidence | ASLEEP | 17.7/35 Income -1.5% · PAT 100% 52% evidence | 8.7/25 ROA 1.7% · ROE -9% · GNPA — 68% evidence | 9.1/20 P/BV 1.23× · P/BV÷ROE — 40% evidence | 4.5/20 RS sector -17.3% · RS bench -31.1% · 1Y -36.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 17.7 + 8.7 + 9.1 + 4.5 = 40 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25The Investment Trust of India LtdTHEINVEST | 38.6/100Mixed-negative evidence69% evidence | BASING | 11.6/35 Income -22.4% · PAT -13.9% 52% evidence | 11.7/25 ROA 2.7% · ROE 4.1% · GNPA — 68% evidence | 8.6/20 P/BV 0.71× · P/BV÷ROE 0.17 70% evidence | 6.7/20 RS sector -13.1% · RS bench -16% · 1Y -37.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 11.7 + 8.6 + 6.7 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Nalwa Sons Investments LtdNSIL | 35.7/100Mixed-negative evidence76% evidence | BASING | 18.7/35 Income -20.3% · PAT 37.2% 86% evidence | 5.8/25 ROA 0.3% · ROE 0.3% · GNPA — 72% evidence | 4.9/20 P/BV 0.19× · P/BV÷ROE 0.56 70% evidence | 6.3/20 RS sector -6.7% · RS bench -13% · 1Y -17.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.7 + 5.8 + 4.9 + 6.3 = 35.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Prime Securities LtdPRIMESECU | 35.4/100Mixed-negative evidence86% evidence | TURNING | 8.8/35 Income 14.4% · PAT -80% 81% evidence | 13.3/25 ROA 4.6% · ROE 4.1% · GNPA — 68% evidence | 3.0/20 P/BV 3.73× · P/BV÷ROE 0.91 100% evidence | 10.3/20 RS sector 0.9% · RS bench -1.6% · 1Y 5.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 8.8 + 13.3 + 3 + 10.3 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Crest Ventures LtdCREST | 34.3/100Adverse evidence86% evidence | ASLEEP | 6.8/35 Income -33.2% · PAT -49.3% 81% evidence | 12.2/25 ROA 2.5% · ROE 3.8% · GNPA — 68% evidence | 7.8/20 P/BV 0.79× · P/BV÷ROE 0.21 100% evidence | 7.5/20 RS sector -1% · RS bench -3.7% · 1Y -6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 6.8 + 12.2 + 7.8 + 7.5 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Dhunseri Investments LtdDHUNINV | 30.2/100Adverse evidence73% evidence | TURNING | 15.1/35 Income -12.3% · PAT 17.1% 62% evidence | 4.8/25 ROA -0.5% · ROE 0.7% · GNPA — 68% evidence | 5.0/20 P/BV 0.24× · P/BV÷ROE 0.36 100% evidence | 5.3/20 RS sector -34.7% · RS bench -3.1% · 1Y -27.3%2 of 6 weeks ahead 70% evidence |
| Exact sum: 15.1 + 4.8 + 5 + 5.3 = 30.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Systematix Corporate Services LtdSYSTMTXC | 28.8/100Adverse evidence74% evidence | ASLEEP | 9.2/35 Income 14.4% · PAT -80% 81% evidence | 12.2/25 ROA 3.2% · ROE 4.6% · GNPA — 68% evidence | 4.4/20 P/BV 2.6× · P/BV÷ROE 0.56 70% evidence | 3.0/20 RS sector -38.5% · RS bench -40.7% · 1Y -50.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 9.2 + 12.2 + 4.4 + 3 = 28.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Oswal Green Tech LtdOSWALGREEN | 27.2/100Adverse evidence75% evidence | BASING | 8.7/35 Income -46.8% · PAT -80% 52% evidence | 8.1/25 ROA 1.1% · ROE 1.5% · GNPA — 68% evidence | 8.0/20 P/BV 0.23× · P/BV÷ROE 0.16 100% evidence | 2.4/20 RS sector -28.3% · RS bench -30.9% · 1Y -51%0 of 12 weeks ahead 100% evidence |
| Exact sum: 8.7 + 8.1 + 8 + 2.4 = 27.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Spice Lounge Food Works LtdSPICELOUNG | 45.2/100Thin evidence · provisional44% evidence | 20.2/35 Income 20.9% · PAT 100% 22% evidence | 11.9/25 ROA — · ROE 8.4% · GNPA — 34% evidence | 3.2/20 P/BV 15.85× · P/BV÷ROE 1.9 70% evidence | 9.9/20 RS sector 0.7% · RS bench -8.4% · 1Y -22.3%2 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 20.2 + 11.9 + 3.2 + 9.9 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Eraaya Lifespaces LtdEBIX | 39.6/100Thin evidence · provisional22% evidence | 17.5/35 Income — · PAT — 0% evidence | 9.3/25 ROA — · ROE -809% · GNPA — 26% evidence | 9.2/20 P/BV 6.36× · P/BV÷ROE — 10% evidence | 3.6/20 RS sector -34.1% · RS bench -39.5% · 1Y -41.4%8 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 17.5 + 9.3 + 9.2 + 3.6 = 39.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is CSL Finance Ltd's share price today?
CSL Finance Ltd trades at ₹212, −33.7% over the past year. The company is valued at ₹483 Cr. The stock sits at the very bottom of its 52-week range (₹212–₹318), −17.0% versus its 200-day average. On the tape, the price is in a downtrend, 48 weeks in. — as of 14 August 2026.
What were CSL Finance Ltd's latest quarterly results?
CSL Finance Ltd reported total income of ₹69.0 Cr and net profit of ₹19.0 Cr for the Mar 26 quarter. Income rose 21.1% and profit rose 0.0% year on year. Earnings per share were ₹8.52. The net margin was 27.5%, 5.8 pp lower than a year earlier. — as of 14 August 2026.
What is CSL Finance Ltd's revenue?
CSL Finance Ltd reported revenue of ₹69.0 Cr in the Mar 26 quarter, +21.1% year on year. For the full FY26 fiscal year, revenue was ₹256 Cr (+18.5%). Over the last 10 years revenue compounded at 19.3% a year. — as of 14 August 2026.
What is CSL Finance Ltd's profit?
CSL Finance Ltd earned ₹19.0 Cr of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹86.0 Cr. The net margin ran 27.5% in the latest quarter. — as of 14 August 2026.
What is CSL Finance Ltd's market cap?
CSL Finance Ltd's market capitalisation is ₹483 Cr at a share price of ₹212. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 14 August 2026.
What is CSL Finance Ltd's P/BV ratio?
CSL Finance Ltd trades at a P/BV of 0.8×, at the 20th percentile of its own 10-year range, against a long-run median of 1.2×. This is a comparison with the stock's own history, not a value call — as of 14 August 2026.
Does CSL Finance Ltd pay a dividend?
Yes — CSL Finance Ltd's dividend payout was 26% of profit in FY26, and it recorded a payout in 10 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 14 August 2026.
Is CSL Finance Ltd overvalued?
On its own history, CSL Finance Ltd looks cheap: its P/BV of 0.8× has been cheaper only 20% of the time in 10 years (long-run median 1.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 14 August 2026.
Is CSL Finance Ltd growing?
The picture is mixed for CSL Finance Ltd: latest-quarter revenue +21.1% year on year, profit +0.0%, and the net margin −5.8 pp at 27.5%. The 10-year compound rates are 19.3% (revenue) and 20.8% (profit). The earnings engine currently reads: mixed — as of 14 August 2026.
How is CSL Finance Ltd performing?
CSL Finance Ltd is in a downtrend, 48 weeks in. Its latest quarter's income rose 21.1% and profit rose 0.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 14 August 2026.
What stage is CSL Finance Ltd in?
Mixed — no clean majority across the growth curves, ROE holding at 15.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +21.1% latest, profit growth +0.0% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 14 August 2026.
Is CSL Finance Ltd in an uptrend?
No — the price is in a downtrend (week 48 of stage 4), trading −17.0% versus its 200-day average and at the very bottom of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 14 August 2026.
Is CSL Finance Ltd beating the market?
Not lately — on a trailing-13-week view CSL Finance Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-07-01), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +817% against the NIFTY 500's +274% — ahead of the index over the full window. — as of 14 August 2026.
Will CSL Finance Ltd's share price go up?
This page publishes no price forecast for CSL Finance Ltd. What it measures instead: the share price is ₹212, the price is in a downtrend 48 weeks in. Its P/BV of 0.8× sits at the 20th percentile of its own 10-year range. — as of 14 August 2026.
Who owns CSL Finance Ltd?
Promoters hold 48.2% of CSL Finance Ltd, foreign institutions 0.1%, domestic institutions 3.5% and the public 46.9% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 2.4 points over 8 quarters. — as of 14 August 2026.
Is CSL Finance Ltd's loan book healthy?
Gross NPA is 1.10% of CSL Finance Ltd's loan book, up from 0.46% a year ago, and net NPA stands at 0.81%. Falling NPAs are a loan book healing; rising NPAs are damage arriving — as of 14 August 2026.
Where is CSL Finance Ltd in its business cycle?
CSL Finance Ltd's FY26 net margin was 33.6%, against a 13-year band of 6.1%–45.2%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 27.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 14 August 2026.
What growth does CSL Finance Ltd's price assume?
At its price on 13 June 2026, CSL Finance Ltd was priced for profit growth of about −2.1% a year. Profit itself has compounded 20.8% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 14 August 2026.
What could break the CSL Finance Ltd story?
The sharpest disagreement: annual EPS moved +19.5% against a −33.7% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 14 August 2026.
Is CSL Finance Ltd a stock worth studying right now?
This is not investment advice. The machine read: CSL Finance Ltd compounds quietly. Returns above 15% and growth without drama — priced like it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 14 August 2026.